Wednesday, July 29, 2020

Roche#39;s Tocilizumab fails to meet primary end points for COVID-19 associated pneumonia

Roche#39;s Tocilizumab fails to meet primary end points for COVID-19 associated pneumonia However, Roche said there was a positive trend in time to hospital discharge in patients treated with Actemra. The median time to discharge or ‘ready to discharge’ for Actemra was 20 days and for placebo was 28 days.

from Moneycontrol Business News https://ift.tt/334PmjR
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Largecap valuations near fair value, time to start deploying: Jyotivardhan Jaipuria

​So, banks are cheap. And second is, at these valuations, a lot of bad news is priced in. So, as we see growth coming back, as we see things...